Center-Authored Papers

Filters: Author is Wagner-Johnston, Nina D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
R
Ghosh N, Karmali R, Rocha V, Woo Ahn K, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, DeLima M et al..  2016.  Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
P
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A et al..  2014.  PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.. The New England journal of medicine. Abstract
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM et al..  2015.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
E
Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS et al..  2016.  Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.. Haematologica.
C
Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP et al..  2015.  Cancer-Related Fatigue, Version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(8):1012-39. Abstract